Received Oct 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
the patient was administered their first dose of GARDASIL 9 on 10/04/2024 and has not yet been administered the second or third doses in the series; No symptoms reported.; This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 04-OCT-2024, the patient was vaccinated with 1st dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection at a total dose of 0.5 mL, administered for prophylaxis (route of administration, anatomical location, lot # and expiration date were not reported). The patient had not yet been administered 2nd and 3rd dose in the series; vaccine schedule interruption of 11 months was reported (Inappropriate schedule of product administration). No symptoms were reported (No adverse event). Lot# is being requested and will be submitted if received.